Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pharma Outsourcing
by MICHAEL MCCOY, C&EN NORTHEAST NEWS BUREAU
April 5, 2004
| A version of this story appeared in
Volume 82, Issue 14
COVER STORY
PHARMA OUTSOURCING
There's a lot of gloom and doom in the pharmaceutical outsourcing business these days. Drug companies are winning a fraction of the new product approvals that they were in the mid-1990s. Many of the big pharmaceutical chemical makers that serve them are saddled with too much capacity bought at prices that were too high.
Yet the drug industry is still a vibrant place. Entrepreneurial companies with interesting therapeutic ideas are developing new drugs, and many of them are outsourcing the scale-up and production of these compounds. Not all of these firms will succeed, but as they strive to turn their ideas into reality, they are a source of new business for pharmaceutical outsourcing providers.
In the pages to follow, C&EN presents four case studies of the relationship between a drug company and a pharmaceutical chemical supplier.
Two of these relationships involve traditional small molecules, one involves a fermentation product, and one involves compound libraries used in drug discovery. Some of the eight companies profiled are large, and some are small; some are old, and some are young. The relationships are unique, but they all have one thing in common: Companies that provide good service are rewarded with follow-up business from their drug industry partners.
Advertisement
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter